KPTI Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~96% gross margins indicate very strong product-level economics for XPOVIO, providing durable contribution margin to fund R&D and commercial scale. This structural profitability at the gross line supports long-term leverage if sales grow and helps insulate unit economics from moderate price pressure.
Phase III SENTRY Efficacy And OS SignalRobust SENTRY spleen-response and an overall survival signal provide durable clinical differentiation and a potential disease‑modifying claim. These high-quality Phase III data materially strengthen regulatory and commercial positioning for selinexor+ruxolitinib in myelofibrosis and support a credible pathway to broader adoption and label expansion.
Lower Debt And Near-term FinancingMaterial reduction in reported debt and a completed ~$50M financing improve near-term solvency and reduce refinancing stress. This stronger capital structure increases the probability management can execute pending regulatory filings and commercial launches without immediate distress, lengthening runway to key catalysts.
Bears Say
Persistent Negative Cash FlowOngoing negative operating and free cash flow (~-$59M TTM) reflect a structural cash burn that will require recurring financing or material revenue scale to correct. Persistent outflows limit strategic optionality, raise dilution risk, and constrain the company's ability to sustain high R&D and commercial investments without external capital.
Deeply Negative Equity BaseSubstantially negative shareholders' equity (~-$266M TTM) materially weakens financial flexibility and increases going-concern sensitivity. This structural capital deficiency makes debt financing or non-dilutive options harder to obtain and heightens the likelihood of dilutive equity or strategic transactions under adverse scenarios.
Short Cash Runway And Financing NeedA runway only into late Q3 2026 forces dependence on near-term financing, milestone receipts, or strategic deals. That timing elevates execution risk: management may need to pursue dilutive financing or strategic transactions before key regulatory clarity, potentially compromising long‑term shareholder outcomes and operational independence.
Karyopharm Therapeutics News
KPTI FAQ
What was Karyopharm Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Karyopharm Therapeutics’s market cap?
Karyopharm Therapeutics’s market cap is CHF35.19M.
When is Karyopharm Therapeutics’s upcoming earnings report date?
Karyopharm Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 86 days.
How were Karyopharm Therapeutics’s earnings last quarter?
Currently, no data Available
Is Karyopharm Therapeutics overvalued?
According to Wall Street analysts Karyopharm Therapeutics’s price is currently Undervalued.
Does Karyopharm Therapeutics pay dividends?
Karyopharm Therapeutics does not currently pay dividends.
What is Karyopharm Therapeutics’s EPS estimate?
Karyopharm Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Karyopharm Therapeutics have?
Currently, no data Available
What happened to Karyopharm Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Karyopharm Therapeutics?
Currently, no hedge funds are holding shares in CH:KPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Karyopharm Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.82 (― Upside)
CHF5.82 (― Upside)
Blogger Sentiment
Neutral
CH:KPTI Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Bearish
Bullish news 20%
Bearish news 80%
Bearish news 80%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.90%
Trailing 12-Months
Company Description
Karyopharm Therapeutics
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
KPTI Company Deck
KPTI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong clinical momentum and significant near-term catalysts: compelling Phase III SENTRY results with a statistically robust spleen response and an intriguing overall survival signal, completed enrollment in EC042 with prior SIENDO data showing deep and durable PFS benefit, ASCO presentation and planned mid-2026 manuscript, and quarter-over-quarter revenue improvement driven by gross-to-net gains. These positives are tempered by competitive pressure that reduced underlying demand for XPOVIO, gross-to-net volatility, continued net losses and high operating spend, and a limited cash runway into late Q3 2026 that may necessitate additional financing or milestone events. Regulatory timing and the need for further data granularity (e.g., deaths attribution) add some near-term uncertainty. On balance, the clinical and strategic highlights are material and potentially value-creating, though execution and financing risks remain.View all CH:KPTI earnings summariesKPTI Stock 12 Month Forecast
Average Price Target
―Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
Century Therapeutics
―
Medicus Pharma Ltd
―